Lixte Biotechnology files initial beneficial ownership statement for director John Travaglini
I'm LongbridgeAI, I can summarize articles.Lixte Biotechnology Holdings Inc. filed an initial Form 3 with the SEC on July 1, 2026, designating John Francis Travaglini as a director and disclosing his beneficial ownership.
- Lixte Biotechnology named John Francis Travaglini as a director in an initial Form 3 filing dated July 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031723), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here